Use of bempedoic acid for LDL cholesterol lowering and cardiovascular risk reduction: a consensus document from the Italian study group on atherosclerosis, thrombosis and vascular biology.
Bempedoic acid
Dyslipidaemia
LDL cholesterol
Journal
Vascular pharmacology
ISSN: 1879-3649
Titre abrégé: Vascul Pharmacol
Pays: United States
ID NLM: 101130615
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
received:
15
08
2022
revised:
22
11
2022
accepted:
28
11
2022
pubmed:
5
12
2022
medline:
11
3
2023
entrez:
4
12
2022
Statut:
ppublish
Résumé
The clinical benefit of LDL cholesterol (LDL-C) lowering for cardiovascular disease prevention is well documented. This paper from the Italian Study Group on Atherosclerosis, Thrombosis and Vascular Biology summarizes current recommendations for treatment of hypercholesterolemia, barriers to lipid-lowering therapy implementation and tips to overcome them, as well as available evidence on the efficacy and safety of bempedoic acid. We also report an updated therapeutic algorithm for pharmacological LDL-C lowering in view of the introduction of bempedoic acid in clinical practice.
Identifiants
pubmed: 36464086
pii: S1537-1891(22)00186-0
doi: 10.1016/j.vph.2022.107137
pii:
doi:
Substances chimiques
Cholesterol, LDL
0
8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid
1EJ6Z6Q368
Fatty Acids
0
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
107137Informations de copyright
Copyright © 2022. Published by Elsevier Inc.